Journal of Clinical Oncology, Vol 15, 2715-2721, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

L Del Mastro, M Venturini, R Lionetto, O Garrone, G Melioli, W Pasquetti, MR Sertoli, G Bertelli, G Canavese, M Costantini and R Rosso
Divisione di Oncologia Medica I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy. marco.venturini@schering-pl.it

PURPOSE: Although erythropoietin (EPO) is known to be useful in treating chemotherapy-induced anemia, few data are available on its potential preventive role. The aim of this study was to evaluate the ability of EPO in preventing the development of clinically significant anemia in patients treated with chemotherapy. PATIENTS AND METHODS: Sixty-two early-stage breast cancer patients undergoing accelerated adjuvant chemotherapy were randomized to receive EPO 150 U/kg three times a week or no additional treatment. Chemotherapy consisted of six cycles of cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF) intravenously on day 1, every 2 weeks with the support of granulocyte colony-stimulating factor (G-CSF), 5 microg/kg subcutaneously from day 4 to day 11. RESULTS: Throughout the six cycles of chemotherapy, EPO-treated patients maintained stable values of hemoglobin, whereas control patients developed a progressive anemia. At the end of chemotherapy, the mean (+/- SD) hemoglobin decrease in the control group was 3.05 g/dL (+/- 1.0; 95% confidence interval [CI], 2.6 to 3.5), whereas in the EPO group it was 0.8 (+/- 1.4; 95% CI, 0.3 to 1.4). Clinically significant anemia (hemoglobin < or = 10 g/dL) occurred in 16 patients (52%; 95% CI, 33 to 69) in the control arm and in no patient (0%; 95% CI, 0 to 14) in the EPO arm (P = .00001). CONCLUSION: EPO prevents anemia in patients undergoing chemotherapy. Further trials are required to identify subsets of patients in which the preventive use of this drug could be cost- effective.

This article has been cited by other articles:

				P. Gascon Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications Oncologist, May 1, 2008; 13(suppl_3): 4 - 10. [Abstract] [Full Text] [PDF]

				C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia JAMA, February 27, 2008; 299(8): 914 - 924. [Abstract] [Full Text] [PDF]

				V. Charu, B. Saidman, A. Ben-Jacob, G. R. Justice, A. S. Maniam, D. Tomita, G. Rossi, T. Rearden, and J. Glaspy A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia Oncologist, October 1, 2007; 12(10): 1253 - 1263. [Abstract] [Full Text] [PDF]

				J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, May 17, 2006; 98(10): 708 - 714. [Abstract] [Full Text] [PDF]

				A. Engert Recombinant human erythropoietin in oncology: current status and further developments Ann. Onc., October 1, 2005; 16(10): 1584 - 1595. [Abstract] [Full Text] [PDF]

				R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF]

				R. C. Leonard, M. Untch, and F. Von Koch Management of anaemia in patients with breast cancer: role of epoetin Ann. Onc., May 1, 2005; 16(5): 817 - 824. [Abstract] [Full Text] [PDF]

				J. Bohlius, S. Langensiepen, G. Schwarzer, J. Seidenfeld, M. Piper, C. Bennett, and A. Engert Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis J Natl Cancer Inst, April 6, 2005; 97(7): 489 - 498. [Abstract] [Full Text] [PDF]

				P. Marec-Berard, J. Y. Blay, M. Schell, M. Buclon, C. Demaret, and I. Ray-Coquard Risk Model Predictive of Severe Anemia Requiring RBC Transfusion After Chemotherapy in Pediatric Solid Tumor Patients J. Clin. Oncol., November 15, 2003; 21(22): 4235 - 4238. [Abstract] [Full Text] [PDF]

				T Ng, G Marx, T Littlewood, and I Macdougall Recombinant erythropoietin in clinical practice Postgrad. Med. J., July 1, 2003; 79(933): 367 - 376. [Abstract] [Full Text] [PDF]

				J. D. Rizzo, A. E. Lichtin, S. H. Woolf, J. Seidenfeld, C. L. Bennett, D. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, S. J. Lee, et al. Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology J. Clin. Oncol., October 1, 2002; 20(19): 4083 - 4107. [Abstract] [Full Text] [PDF]

				J. D. Rizzo, A. E. Lichtin, S. H. Woolf, J. Seidenfeld, C. L. Bennett, D. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, S. J. Lee, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology Blood, September 18, 2002; 100(7): 2303 - 2320. [Abstract] [Full Text] [PDF]

				J. Seidenfeld, M. Piper, C. Flamm, V. Hasselblad, J. O. Armitage, C. L. Bennett, M. S. Gordon, A. E. Lichtin, J. L. Wade III, S. Woolf, et al. Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials J Natl Cancer Inst, August 15, 2001; 93(16): 1204 - 1214. [Abstract] [Full Text] [PDF]

				J. D. Rizzo, J. Seidenfeld, M. Piper, N. Aronson, A. Lichtin, and T. J. Littlewood Erythropoietin: A Paradigm for the Development of Practice Guidelines Hematology, January 1, 2001; 2001(1): 10 - 30. [Abstract] [Full Text] [PDF]

				I. Ray-Coquard, A. Le Cesne, M. T. Rubio, J. Mermet, C. Maugard, A. Ravaud, C. Chevreau, C. Sebban, T. Bachelot, P. Biron, et al. Risk Model for Severe Anemia Requiring Red Blood Cell Transfusion After Cytotoxic Conventional Chemotherapy Regimens J. Clin. Oncol., September 1, 1999; 17(9): 2840 - 2840. [Abstract] [Full Text] [PDF]

				L. D. Mastro and M. Venturini Strategies for the Use of Epoetin Alfa in Breast Cancer Patients Oncologist, October 1, 1998; 3(5): 314 - 318. [Abstract] [Full Text]